NASDAQ:VTGN Vistagen Therapeutics (VTGN) Stock Price, News & Analysis $2.38 -0.06 (-2.26%) As of 12:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Vistagen Therapeutics Stock (NASDAQ:VTGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vistagen Therapeutics alerts:Sign Up Key Stats Today's Range$2.35▼$2.4250-Day Range$2.03▼$2.9152-Week Range$1.90▼$4.30Volume44,264 shsAverage Volume171,217 shsMarket Capitalization$68.55 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingStrong Buy Company OverviewVistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.Read More… Vistagen Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks24th Percentile Overall ScoreVTGN MarketRank™: Vistagen Therapeutics scored higher than 24% of companies evaluated by MarketBeat, and ranked 821st out of 917 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Vistagen Therapeutics.Read more about Vistagen Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vistagen Therapeutics are expected to grow in the coming year, from ($1.77) to ($1.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vistagen Therapeutics is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vistagen Therapeutics is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVistagen Therapeutics has a P/B Ratio of 0.84. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Vistagen Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.82% of the float of Vistagen Therapeutics has been sold short.Short Interest Ratio / Days to CoverVistagen Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vistagen Therapeutics has recently decreased by 7.96%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVistagen Therapeutics does not currently pay a dividend.Dividend GrowthVistagen Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.82% of the float of Vistagen Therapeutics has been sold short.Short Interest Ratio / Days to CoverVistagen Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vistagen Therapeutics has recently decreased by 7.96%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Vistagen Therapeutics this week, compared to 1 article on an average week.MarketBeat Follows3 people have added Vistagen Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vistagen Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.29% of the stock of Vistagen Therapeutics is held by insiders.Percentage Held by Institutions78.39% of the stock of Vistagen Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vistagen Therapeutics' insider trading history. Receive VTGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vistagen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VTGN Stock News HeadlinesVistagen to Present at the 2025 American Society of Clinical Psychopharmacology ConferenceMay 23 at 8:30 AM | businesswire.comVistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 ConferenceApril 17, 2025 | businesswire.comWashington Is Broke—and Eyeing Your Savings NextWashington is running out of money…And guess where they'll look next? When governments go broke, they take from the people. It's happened before, and it's happening again. The Department of Justice just admitted that cash isn't legally YOUR property.May 23, 2025 | Priority Gold (Ad)VistaGen at Stifel 2025: Pioneering Acute SAD TreatmentMarch 20, 2025 | investing.comVistagen to Present at the 2025 Anxiety and Depression Association ConferenceMarch 19, 2025 | businesswire.comVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2025 Earnings Call TranscriptFebruary 15, 2025 | msn.comVistaGen’s Earnings Call: Progress and ChallengesFebruary 14, 2025 | tipranks.comVistagen: Pherine Candidate Proof Of Concept Continues With Fifth IndicationFebruary 14, 2025 | seekingalpha.comSee More Headlines VTGN Stock Analysis - Frequently Asked Questions How have VTGN shares performed this year? Vistagen Therapeutics' stock was trading at $2.95 at the beginning of the year. Since then, VTGN stock has decreased by 20.0% and is now trading at $2.36. View the best growth stocks for 2025 here. How were Vistagen Therapeutics' earnings last quarter? Vistagen Therapeutics, Inc. (NASDAQ:VTGN) posted its earnings results on Thursday, February, 13th. The company reported ($0.46) EPS for the quarter, beating analysts' consensus estimates of ($0.48) by $0.02. The company had revenue of $230 billion for the quarter, compared to the consensus estimate of $0.18 million. Vistagen Therapeutics had a negative net margin of 6,777.08% and a negative trailing twelve-month return on equity of 48.12%. Read the conference call transcript. When did Vistagen Therapeutics' stock split? Vistagen Therapeutics's stock reverse split before market open on Wednesday, June 7th 2023. The 1-30 reverse split was announced on Wednesday, June 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are Vistagen Therapeutics' major shareholders? Vistagen Therapeutics' top institutional shareholders include ADAR1 Capital Management LLC (1.46%), Cubist Systematic Strategies LLC (0.03%), Simplex Trading LLC and Caption Management LLC. Insiders that own company stock include Commodore Capital Lp, Venrock Healthcare Capital Par, Shawn Singh, Reid G Adler and Jerry B Gin. View institutional ownership trends. How do I buy shares of Vistagen Therapeutics? Shares of VTGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vistagen Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vistagen Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET). Company Calendar Last Earnings2/13/2025Today5/23/2025Next Earnings (Estimated)6/10/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VTGN CIK1411685 Webwww.vistagen.com Phone(650) 577-3600Fax888-482-2602Employees40Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,360,000.00 Net Margins-6,777.08% Pretax Margin-6,775.93% Return on Equity-48.12% Return on Assets-43.80% Debt Debt-to-Equity RatioN/A Current Ratio9.35 Quick Ratio9.35 Sales & Book Value Annual Sales$698,000.00 Price / Sales98.21 Cash FlowN/A Price / Cash FlowN/A Book Value$2.81 per share Price / Book0.85Miscellaneous Outstanding Shares28,862,000Free Float28,490,000Market Cap$68.55 million OptionableOptionable Beta0.67 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:VTGN) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vistagen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vistagen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.